The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
Orbis Medicines’ Series A round of funding was led by New Enterprise Associates. The startup is developing oral macrocyclic drugs for targets validated by blockbuster biologic medications that must be administered by injection. The post A Startup’s €90M Financing for Oral Peptide Drugs Includes Backing from Eli Lilly appeared first on MedCity News.
Senators have launched an inquiry into companies paid billions in taxpayer dollars to build eligibility systems for Medicaid, expressing concern that error-riddled technology and looming work requirements “will cause Americans to lose Medicaid coverage to this bureaucratic maze.” The letters, dated Oct. 10, were sent to four companies and follow a KFF Health News investigation…
Though anselamimab failed its Phase 3 test in light chain amyloidosis, AstraZeneca points to encouraging results in a pre-defined patient subgroup — which may not be a winning strategy. Prothena resurrected its failed drug candidate for the disease based on a subgroup analysis, only to see that antibody fall short in a pivotal study. The…
It’s time that the healthcare industry transitioned from isolated point solutions to an integrated care model that incorporates remote monitoring and virtual care management. The post Acuity-driven Care — Leveraging Multi-level Monitoring for Complex Needs appeared first on MedCity News.
Here are three things providers should consider when it comes to Medicare. The post Changes Are Coming to 2026 Medicare Benefits appeared first on MedCity News.
From AI to value-based care, three VCs shared their controversial takes on healthcare during a recent panel discussion at the MedCity INVEST conference. The post 3 Health Investors Share Their Most Controversial Industry Takes appeared first on MedCity News.
The NYC Health Department released a report highlighting the immigrant contributions to the city’s health
Hone Health’s Series A round included participation from Tribe Capital, PIF, Republic Capital, Vibe VC, Humbition, Hanwha, Gaingels, Looking Glass Capital, FJ Labs and Agent Capital. In total, the company has raised $39 million. The post Telehealth Clinic Hone Health Secures $33M, Acquires Home Health Company appeared first on MedCity News.
Cytokinetics drug Myqorzo won FDA approval for treating obstructive hypertrophic cardiomyopathy, or oHCM. Compared to Bristol Myers Squibb’s projected blockbuster drug Camzyos, the Cytokinetics daily pill has less restrictive safety and monitoring requirements, giving it a competitive advantage, according to analysts. The post FDA Approval Puts New Cytokinetics Heart Drug in Competition With Fast-Growing BMS…